SC13
Based on 1 publication(s) in Google Scholar
SC13 is an orally active, selective Flap structure-specific endonuclease 1 (FEN1) inhibitor and mu opioid receptor (MOR) activator. SC13 impairs DNA damage repair and induces apoptosis in cancer cells. SC13 activates cGAS-STING signaling, increases chemokine secretion, and promotes CAR-T cell infiltration at solid tumour sites. SC13 can be used for the research of solid tumours and pain.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 2839142-69-5
- Formule: C26H30N2O5
- Masse moléculaire:450.53
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) SC13
MoreVoir tous les produits spécifiques à Isoform Opioid Receptor
More
Activité biologique
|
μ Opioid Receptor/MOR |
SC13 (20 μM; 48 h) induces DNA double-strand break accumulation and cytoplasmic dsDNA leakage in HeLa, MCF-7, and SKOV-3 human cancer cells[1].
SC13 (20 μM; 48 h) activates the cGAS-STING pathway and increases chemokine (CCL5, CXCL10) and IFN-β expression in HeLa, MCF-7, and SKOV-3 human cancer cells, dependent on STING signalling[1].
SC13 (20 μM; 48 h) induces HeLa, MCF-7, and SKOV-3 cells to secrete chemokines that promote MSLN CAR-T cell migration via a TBK1-dependent mechanism[1].
SC13 (20 μM; 48 h) induces mild DNA damage but does not impair proliferation, CAR expression, or cytotoxic function of MSLN CAR-T cells[1].
SC13 potently inhibits cAMP production in human mu-opioid receptor-expressing HEK-T cells with an EC50 of 7.25 nM and maximum efficacy[2].
SC13 recruits β-arrestin2 in human mu-opioid receptor-expressing HTLA cells with low potency (EC50 = 11000 nM) and moderate efficacy[2].
SC13 acts as a partial agonist for Gi-1 G-protein activation in human mu-opioid receptor-expressing cells, with high selectivity for MOR over DOR and KOR[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HeLa, MCF-7, SKOV-3 human cancer cell lines
-
Concentration:20 μM
-
Incubation Time:48 h
-
Result:Upregulated γ-H2AX (a marker of DNA double-strand breaks) in HeLa, MCF-7, and SKOV-3 cells.
Increased cytoplasmic dsDNA leakage in these cell lines.
-
Cell Line:HeLa, MCF-7, SKOV-3 human cancer cell lines
-
Concentration:20 μM
-
Incubation Time:48 h
-
Result:Activated the cGAS-STING pathway and increased chemokine (CCL5, CXCL10) and IFN-β expression, dependent on STING signalling.
-
Cell Line:MSLN CAR-T cells, HeLa, MCF-7, SKOV-3 human cancer cell lines
-
Concentration:20 μM
-
Incubation Time:48 h
-
Result:Significantly increased the number of migrating MSLN CAR-T cells compared to medium from vehicle-treated tumour cells; this effect was blocked by pre-treatment of tumour cells with the TBK1 inhibitor Amlexanox.
Increased secretion of CCL5 and CXCL10 in the supernatant of SC13-treated tumour cells.
SC13 (1-15 mg/kg; s.c. or p.o.; single dose; 10 mg/kg) produces MOR-dependent antinociception in mice with an ED50 of 3.05 mg/kg s.c., and maintains efficacy via oral administration[2].
SC13 (15 mg/kg; s.c.; daily; 2 days) does not induce reward or dysphoria in Mus musculus[2].
SC13 (15 mg/kg; s.c.; single dose) does not inhibit gastrointestinal transit in mice[2].
SC13 (45 mg/kg; s.c.; single dose) does not induce respiratory depression or hyperlocomotion in mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:B-NDG (6 weeks old; injected 5 × 106 HeLa cells subcutaneously into the mice)[1]
-
Dosage:5 mg/kg
-
Administration:i.p.; every other day for 32 days
-
Result:Reduced mean tumour weight to ~0.2 g compared to ~0.5 g in CAR-T alone group.
Increased intratumoural CD8+ T-cell infiltration to 18.65% of tumour-infiltrating cells compared to 6.95% in CAR-T alone group.
Increased CD8 signal intensity ~4-fold compared to CAR-T alone group.
Elevated CCL5 fluorescence intensity ~3-fold compared to CAR-T alone group.
Elevated CXCL10 fluorescence intensity ~2-fold compared to CAR-T alone group.
Caused no significant change in mouse body weight.
Showed no exacerbated organ damage to heart, liver, spleen, lung, or kidney.
-
Animal Model:C57BL/6J mice (20-32 g)[2]
-
Dosage:1 mg/kg; 3 mg/kg; 10 mg/kg; 15 mg/kg
-
Administration:s.c. or p.o.; single dose
-
Result:Produced dose-dependent antinociception.
Reached a maximum of ~30% MPE at 20 minutes post-administration with 1 mg/kg s.c..
Reached ~30% MPE at 20 minutes post-administration with 3 mg/kg s.c..
Reached 100% MPE at 20 minutes post-administration with 10 mg/kg s.c..
Achieved an ED50 of 3.05 mg/kg s.c. for antinociception.
Showed significantly reduced antinociception in MOR knockout mice, but remained intact in KOR knockout and DOR knockout mice.
Reached a peak of 87% MPE at 30 minutes post-administration with 10 mg/kg p.o..
-
Animal Model:C57BL/6J mice (20-32 g)[2]
-
Dosage:15 mg/kg
-
Administration:s.c.; daily; 2 days
-
Result:Produced no significant conditioned place preference or aversion.
Showed no statistically significant difference in time spent in the drug-paired compartment compared to pre-conditioning.
-
Animal Model:C57BL/6J mice (20-32 g)[2]
-
Dosage:15 mg/kg
-
Administration:s.c.; single dose
-
Result:Had no significant effect on gastrointestinal transit.
Resulted in charcoal traveling 30.8 cm, a value indistinguishable from saline-treated mice.
-
Animal Model:C57BL/6J mice (20-32 g)[2]
-
Dosage:45 mg/kg
-
Administration:s.c.; single dose
-
Result:Showed no statistically significant respiratory depression compared to vehicle.
Had breath rate comparable to vehicle/saline controls at all time points except 180 and 200 minutes, where it showed a slight increase.
Produced no significant hyperlocomotion.
Had ambulation distance indistinguishable from vehicle/saline controls at all time points.
Chemical Information
-
CAS No. 2839142-69-5
-
Masse moléculaire 450.53
-
Formule C26H30N2O5
-
SMILES
O=C(OC)/C([C@@H](C[C@]12[H])[C@H](CC)CN1CC[C@@]3(O)C2=NC4=C3C(C5=COC=C5)=CC=C4)=C/OC
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
2025 Mar 10;16(1):2401. PMID: 40064914
Pureté et documentation
Références
[1]. Dong Y, et al. FEN1 inhibitor SC13 promotes CAR-T cells infiltration into solid tumours through cGAS-STING signalling pathway. Immunology. 2023;170(3):388-400. [Content Brief]
[2]. Chakraborty S, et al. A Novel Mitragynine Analog with Low-Efficacy Mu Opioid Receptor Agonism Displays Antinociception with Attenuated Adverse Effects. J Med Chem. 2021;64(18):13873-13892. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
SC13 Related Classifications
HY-139678 Related Classifications
Powered by Bioz